PAION LAUNCHES XERAVA FOR THE TREATMENT OF COMPLICATED INTRA-ABDOMINAL INFECTIONS IN ADULTS IN THE NETHERLANDS
Dr. Jim Phillips, Chief Executive Officer of PAION AG, stated: "XERAVA is an important new treatment option for patients suffering from serious intra-abdominal infections. With its broad-spectrum antibacterial activity, we believe XERAVA offers an urgently needed alternative to treat life-threatening infections caused by multidrug-resistant pathogens. We are excited about our third product launch in two months to bring new treatment options to the medical community." PAION is currently launching all of its products - Byfavo(R), GIAPREZA(R) and XERAVA(R) - in a staggered manner by country so that by the end of 2022, launches are planned to have been conducted in most key European markets.
###About complicated intra-abdominal infections (cIAI) Intra-abdominal infections are common in clinical practice and comprise a wide variety of clinical presentations and differing sources of infection. According to the Infectious Diseases Society of America (IDSA), a complicated intra-abdominal infection is defined as an infection that extends beyond the wall of a hollow viscus of origin into the abdominal cavity while being associated with an abscess or peritonitis.
About XERAVA(R) (eravacycline) XERAVA(R) (eravacycline) for injection is a novel fluorocycline of the tetracycline class. XERAVA(R) is an antibiotic used to treat complicated intra-abdominal infections (cIAI) in adults.
The mechanism of action of eravacycline is to interfere with bacterial protein synthesis by binding to the ribosomal subunit 30S, thereby preventing the incorporation of amino acid residues into extended peptide chains.
XERAVA(R) has been shown to be as effective as alternative antibiotics in two main trials in adults with cIAI. The main indicator of efficacy in both trials was the cure rate of infections. In the first trial, involving 538 patients, XERAVA(R) was compared with the antibiotic ertapenem. After about one month, 87% of patients treated with XERAVA(R) were cured of their infection, compared with 89% of patients treated with ertapenem. In the second trial, involving 499 patients, XERAVA(R) was compared with meropenem (a carbapenem antibiotic commonly used in Europe in this indication). After about one month, 92% of patients treated with XERAVA(R) and 92% of patients treated with meropenem were cured of their infection.
The European Summary of Product Characteristics is available on the European Medicines Agency website:https://www.ema.europa.eu/en/medicines/human/EPAR/xerava
About PAION PAION AG is a publicly listed specialty pharmaceutical company with innovative drugs to be used in hospital-based sedation, anesthesia and critical care services. PAION's lead compound is remimazolam, an intravenous, ultra-short-acting and controllable benzodiazepine sedative/anesthetic. Remimazolam is partnered in multiple territories outside of Europe. Remimazolam is approved in the U.S., the EU/EEA/UK, South Korea and China for procedural sedation and in Japan and South Korea for general anesthesia.
In addition to Byfavo(R) (remimazolam), PAION has two further products, GIAPREZA(R) (angiotensin II) and XERAVA(R) (eravacycline), in its portfolio. GIAPREZA(R) is a vasoconstrictor indicated for the treatment of refractory hypotension in adults with septic or other distributive shock who remain hypotensive despite adequate volume restitution and application of catecholamines and other available vasopressor therapies. XERAVA(R) is a novel fluorocycline type of antibiotic indicated for the treatment of complicated intra-abdominal infections in adults.
PAION's mission is to be a leading specialty pharmaceutical company in the fields of anesthesia and critical care by bringing novel products to market to benefit patients, doctors and other stakeholders in healthcare.
PAION is headquartered in Aachen (Germany).
Contact Ralf Penner Vice President Investor Relations/Public Relations PAION AG Heussstrasse 25 52078 Aachen - Germany Phone +49 241 4453-152 E-mail email@example.com
Disclaimer: This release contains certain forward-looking statements concerning the future business of PAION AG. These forward-looking statements contained herein are based on the current expectations, estimates and projections of PAION AG' management as of the date of this release. They are subject to a number of assumptions and involve known and unknown risks, uncertainties and other factors. Should actual conditions differ from PAION's assumptions, actual results and actions may differ materially from any future results and developments expressed or implied by such forward-looking statements. Considering the risks, uncertainties and other factors involved, recipients should not rely unreasonably upon these forward-looking statements. PAION AG has no obligation to periodically update such forward-looking statements to reflect future events or developments.
01.09.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.deLanguage: English Company: PAION AG Heussstra?e 25 52078 Aachen
Germany Phone: +49 (0)241-4453-0 Fax: +49 (0)241-4453-100 E-mail: firstname.lastname@example.org Internet: www.paion.com ISIN: DE000A0B65S3 WKN: A0B65S Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange EQS News ID: 1230117 ? End of News DGAP News Service